ClinicalTrials.gg
RecruitingNCT04682483CSWGUpdated Nov 16, 2026

Cardiogenic Shock Working Group Registry

An observational study in Cardiogenic Shock, sponsored by Tufts Medical Center. Recruiting at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Tufts Medical Center · Observational

How we know

From the registry’s dates

  • Started Dec 2017; still recruiting 8 years 11 months later.
Updated Nov 16, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.

Planned enrollment
2nd of 25
20,000 · median 124
Started
2017
with 1 other
Observational
25 of 50
9 open now
Primary completion
2027-12
later than 12 of 22 live
Registered
19th of 50
by date
Lead sponsor
3 of 50
Tufts Medical Center

Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 2nd largest by planned enrollment of the 25 observational ones that give a count, is one of 2 that started in 2017, is one of 25 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 19th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Shock, Cardiogenic with a site in United States, or all of them as a file.
02

Study summary

The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.

Read the detailed description

The Cardiogenic Shock Working Group is an Academic Research Consortium involving multiple medical centers within the United States and includes a multicenter registry for patients with cardiogenic shock. De-identified clinical variables are collected from medical records and follow-up phone calls. There is currently no central database for cardiogenic shock, therefore analysis of cardiogenic shock on a larger scale is limited. A goal of the Cardiogenic Shock Working Group is to create a centralized registry, compiled of data from multiple institutions, to analyze clinical outcomes. The Cardiogenic Shock Working Group Registry will include a retrospective arm, where data is collected during the course of the hospital stay, and a prospective arm, where long-term outcomes will be assessed.

03

Conditions studied

  • Cardiogenic Shock

Keywords

  • Cardiogenic Shock
  • mechanical circulatory support
  • hemodynamics
  • heart failure
  • acute myocardial infarction
  • registry
  • critical care
  • clinical outcomes research
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People who are 18 or older who have an official diagnosis of cardiogenic shock.

Eligibility criteria

Inclusion Criteria:

  • Patients must have cardiogenic shock.

Cardiogenic shock is defined by at least one of the two categories below:

  1. At least 2 of the following concurrently at any point during the index hospitalization:

    • Cardiac Index \< 2.2
    • PAPI \< 1.0
    • Cardiac Power Output ≤ 0.6
    • MAP \< 60mmHg or a >30mmHg drop in MAP from baseline
    • SBP \< 90mmHg or a >30mmHg drop in SBP from baseline
    • Pulse > 100
  2. Require at least one acute mechanical circulatory support device, vasopressor or inotrope to maintain values above the above target.

Post-cardiotomy patients must meet the inclusion criteria 72 hours after their surgery to be included in this registry.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
20,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Cardiogenic Shock Patients

    Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below. 1. Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP \< 60mmHg or a \>30mmHg drop in MAP from baseline, SBP \< 90mmHg or a \>30mmHg drop in SBP from baseline, Pulse \> 100, Cardiac Index \< 2.2, Cardiac Power Output ≤ 0.6 or PAPI \< 1.0. 2. Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets.

    Drug: Vasopressor · Drug: Inotrope · Device: Acute Mechanical Circulatory Support Devices

Interventions

  • The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.

  • DrugInotrope

    Inotropes include dobutamine and milrinone.

  • DeviceAcute Mechanical Circulatory Support Devices

    Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.

06

What researchers measure

Primary outcomes

  1. Rate of Mortality

    Death in subjects during the time frame.

    Time frame: 30 days after discharge

  2. Rate of Mortality

    Death in subjects during the time frame.

    Time frame: 1 year after discharge

Secondary outcomes

  1. Rate of Re-hospitalization

    We will be observing if patient was hospitalized again during the 1 year-time frame. We will collect information on surgeries and interventions during the course of rehospitalization.

    Time frame: 30 day after discharge

  2. Rate of Re-hospitalization

    We will be observing if patient was hospitalized again during the 1 year-time frame. We will collect information on surgeries and interventions during the course of rehospitalization.

    Time frame: 1 year after discharge

  3. New York Heart Association (NYHA) Class

    NYHA Classification provides a way to classify the stages of heart failure. Class I- No symptoms and no limitation in ordinary physical activity Class II- Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV - Severe limitations

    Time frame: 30 day after discharge

  4. New York Heart Association (NYHA) Class

    NYHA Classification provides a way to classify the stages of heart failure. Class I- No symptoms and no limitation in ordinary physical activity Class II- Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV - Severe limitations

    Time frame: 1 year after discharge

07

Study locations

19 of 22 sites recruiting
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northwestern Medicine
    Chicago, Illinois 60611, United States
    Recruiting
    • Esther Vorovich, MD · Contact
    • Esther Vorovich · Principal investigator
  • University of Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • Sandeep Nathan, MD · Contact
    • Sandeep Nathan, MD · Principal investigator
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Onyedika J. Ilonze, MD · Contact
    • Onyedika J. Ilonze, MD · Principal investigator
  • Maine Medical Center
    Portland, Maine 04102, United States
    Completed

    Not enrolling at this site — choose another above.

  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
    Recruiting
    • Faisal Rahman, MD · Contact
    • Faisal Rahman, MD · Principal investigator
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Van-Khue Ton, MD · Contact
    • Van-Khue Ton, MD · Principal investigator
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
    • Arthur R Garan · Contact
    • Arthur R Garan, MD · Principal investigator
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
    • Scott Lundgren, DO · Contact
    • Scott Lundgren, DO · Principal investigator
  • Hackensack Meridian Health
    Hackensack, New Jersey 07601, United States
    Completed

    Not enrolling at this site — choose another above.

  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
    • Justin Fried, MD · Contact
    • Justin Fried, MD · Principal investigator
  • Providence St. Vincent Heart Clinic
    Portland, Oregon 97225, United States
    Recruiting
    • Vidang P. Nguyen, MD · Contact
    • Vidang P. Nguyen, MD · Principal investigator
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Conrad Macon, MD · Contact
    • Conrad Macon · Principal investigator
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Joyce W. Wald, DO · Contact
    • Joyce W. Wald, DO · Principal investigator
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
    • Karthikeyan Ranganathan, MD · Contact
    • Karthikeyan Ranganathan, MD · Principal investigator
  • University Of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15261, United States
    Recruiting
    • Gavin Hickey, MD · Contact
    • Gavin Hickey, MD · Principal investigator
  • Baylor Scott & White Advanced Heart Failure Clinic
    Dallas, Texas 75201, United States
    Recruiting
    • Cesar Guerrero, MD · Contact
    • Cesar Guerrero, MD · Principal investigator
  • University of Texas Medical Branch
    Galveston, Texas 77555, United States
    Recruiting
    • Wissam Khalife, MD · Contact
    • Wissam Khalife · Contact
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
    • : Ju H Kim, MD · Contact
    • Ju H Kim, MD · Principal investigator
  • Inova Health System
    Falls Church, Virginia 22042, United States
    Recruiting
    • Shashank Sinha, MD, MSc · Contact
    • Shashank Sinha, MD, MSc · Principal investigator
  • University of Washington Medical Center
    Seattle, Washington 98195-9472, United States
    Recruiting
    • Sunu Thomas, MD · Contact
    • Sunu Thomas, MD · Principal investigator
08

References and documents

Publications

  • Kapur NK, Thayer KL, Zweck E. Cardiogenic Shock in the Setting of Acute Myocardial Infarction. Methodist Debakey Cardiovasc J. 2020 Jan-Mar;16(1):16-21. doi: 10.14797/mdcj-16-1-16. PubMed 32280413 ↗
  • Pahuja M, Chehab O, Ranka S, Mishra T, Ando T, Yassin AS, Thayer KL, Shah P, Kimmelstiel CD, Salehi P, Kapur NK. Incidence and clinical outcomes of stroke in ST-elevation myocardial infarction and cardiogenic shock. Catheter Cardiovasc Interv. 2021 Feb 1;97(2):217-225. doi: 10.1002/ccd.28919. Epub 2020 Apr 30. PubMed 32352638 ↗
  • Thayer KL, Zweck E, Ayouty M, Garan AR, Hernandez-Montfort J, Mahr C, Morine KJ, Newman S, Jorde L, Haywood JL, Harwani NM, Esposito ML, Davila CD, Wencker D, Sinha SS, Vorovich E, Abraham J, O'Neill W, Udelson J, Burkhoff D, Kapur NK. Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock. Circ Heart Fail. 2020 Sep;13(9):e007099. doi: 10.1161/CIRCHEARTFAILURE.120.007099. Epub 2020 Sep 9. PubMed 32900234 ↗
  • Whitehead E, Thayer K, Kapur NK. Clinical trials of acute mechanical circulatory support in cardiogenic shock and high-risk percutaneous coronary intervention. Curr Opin Cardiol. 2020 Jul;35(4):332-340. doi: 10.1097/HCO.0000000000000751. PubMed 32487943 ↗
  • Kapur NK, Whitehead EH, Thayer KL, Pahuja M. The science of safety: complications associated with the use of mechanical circulatory support in cardiogenic shock and best practices to maximize safety. F1000Res. 2020 Jul 29;9:F1000 Faculty Rev-794. doi: 10.12688/f1000research.25518.1. eCollection 2020. PubMed 32765837 ↗
  • Garan AR, Kanwar M, Thayer KL, Whitehead E, Zweck E, Hernandez-Montfort J, Mahr C, Haywood JL, Harwani NM, Wencker D, Sinha SS, Vorovich E, Abraham J, O'Neill W, Burkhoff D, Kapur NK. Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality. JACC Heart Fail. 2020 Nov;8(11):903-913. doi: 10.1016/j.jchf.2020.08.012. PubMed 33121702 ↗
  • Whitehead EH, Thayer KL, Burkhoff D, Uriel N, Ohman EM, O'Neill W, Kapur NK. Central Venous Pressure and Clinical Outcomes During Left-Sided Mechanical Support for Acute Myocardial Infarction and Cardiogenic Shock. Front Cardiovasc Med. 2020 Aug 28;7:155. doi: 10.3389/fcvm.2020.00155. eCollection 2020. PubMed 33005634 ↗
  • Pahuja M, Ranka S, Chehab O, Mishra T, Akintoye E, Adegbala O, Yassin AS, Ando T, Thayer KL, Shah P, Kimmelstiel CD, Salehi P, Kapur NK. Incidence and clinical outcomes of bleeding complications and acute limb ischemia in STEMI and cardiogenic shock. Catheter Cardiovasc Interv. 2021 May 1;97(6):1129-1138. doi: 10.1002/ccd.29003. Epub 2020 May 30. PubMed 32473083 ↗
  • Hernandez-Montfort J, Kanwar M, Sinha SS, Garan AR, Blumer V, Kataria R, Whitehead EH, Yin M, Li B, Zhang Y, Thayer KL, Baca P, Dieng F, Harwani NM, Guglin M, Abraham J, Hickey G, Nathan S, Wencker D, Hall S, Schwartzman A, Khalife W, Li S, Mahr C, Kim J, Vorovich E, Pahuja M, Burkhoff D, Kapur NK. Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic Shock. JACC Heart Fail. 2023 Feb;11(2):176-187. doi: 10.1016/j.jchf.2022.10.002. Epub 2022 Oct 31. PubMed 36342421 ↗
  • Kapur NK, Kanwar M, Sinha SS, Thayer KL, Garan AR, Hernandez-Montfort J, Zhang Y, Li B, Baca P, Dieng F, Harwani NM, Abraham J, Hickey G, Nathan S, Wencker D, Hall S, Schwartzman A, Khalife W, Li S, Mahr C, Kim JH, Vorovich E, Whitehead EH, Blumer V, Burkhoff D. Criteria for Defining Stages of Cardiogenic Shock Severity. J Am Coll Cardiol. 2022 Jul 19;80(3):185-198. doi: 10.1016/j.jacc.2022.04.049. PubMed 35835491 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Dec 2027, 120 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 120 months is above that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jan 2026 → Dec 2027 and completion Jun 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 23, 2020
StartActual
Dec 4, 2017
Primary completionEst.
Dec 2027was Jan 2026
CompletionEst.
Dec 2027was Jun 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added. 3 sites changed recruiting status (3 now completed)
Show 3 sites
  • Cleveland Clinic Florida · Weston, United StatesRecruiting→Completed
  • Maine Medical Center · Portland, United StatesRecruiting→Completed
  • Hackensack Meridian Health · Hackensack, United StatesRecruiting→Completed
Show 6 added (6 United States)
  • Indiana University Health · Indianapolis, United States
  • Johns Hopkins University · Baltimore, United States
  • Massachusetts General Hospital · Boston, United States
  • University of Nebraska Medical Center · Omaha, United States
  • Oregon Health and Science University · Portland, United States
  • University of Pennsylvania · Philadelphia, United States
Nov 16, 2026
Primary completion
Jan 1, 2026→Dec 2027
Oct 27, 2026
Study completion
Jun 1, 2026→Dec 2027
Oct 27, 2026
Enrollment
5000→20000
Oct 27, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • Cleveland Clinic Florida · Weston, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Maine Medical Center · Portland, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Hackensack Meridian Health · Hackensack, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Providence St. Vincent Heart Clinic · Portland, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • Allegheny General Hospital · Pittsburgh, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • Baylor Scott & White Advanced Heart Failure Clinic · Dallas, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • University of Washington Medical Center · Seattle, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    6 sites added. 3 sites changed recruiting status (3 now completed)
    Show 3 sites
    • Cleveland Clinic Florida · Weston, United StatesRecruiting→Completed
    • Maine Medical Center · Portland, United StatesRecruiting→Completed
    • Hackensack Meridian Health · Hackensack, United StatesRecruiting→Completed
    Show 6 added (6 United States)
    • Indiana University Health · Indianapolis, United States
    • Johns Hopkins University · Baltimore, United States
    • Massachusetts General Hospital · Boston, United States
    • University of Nebraska Medical Center · Omaha, United States
    • Oregon Health and Science University · Portland, United States
    • University of Pennsylvania · Philadelphia, United States
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • Cleveland Clinic Florida · Weston, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Maine Medical Center · Portland, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Hackensack Meridian Health · Hackensack, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Providence St. Vincent Heart Clinic · Portland, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • Allegheny General Hospital · Pittsburgh, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • Baylor Scott & White Advanced Heart Failure Clinic · Dallas, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • University of Washington Medical Center · Seattle, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 27, 2026
    Primary completion Jan 1, 2026→Dec 2027
    Study completion Jun 1, 2026→Dec 2027
    Enrollment 5000→20000
    + 6 other changes: index terms, verification date, oversight details, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04682483
Collaborators
Abbott, Boston Scientific Corporation, Abiomed Inc., Getinge Group
Responsible party
Sponsor
First posted
Dec 23, 2020
Start date
Dec 4, 2017
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Navin K Kapur, MD
Contact
nkapur@tuftsmedicalcenter.org
6176368252
A. Reshad Garan, MD
study director · Beth Israel Deaconess Medical Center
Claudius Mahr, DO
study director · University of Washington
Jaime Hernandez-Montfort, MD
study director · Saint Francis Health System
Daniel Burkhoff, MD PhD
study director · CardioVascular Research Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion